2022 Full Year Guidance and Strategic Outlook
Overview - Execution despite macro challenges
•
•
•
Delivered Core Sales Growth* of 5.4% and Adjusted EBITDA margin* of 19.7%
Disciplined execution delivered MSD core sales growth, led by our Ortho and Implant
businesses while adjusted EBITDA margin was the highest in the last 4 quarters
The Envista Business System (EBS), and its focus on continuous improvement,
advances our long-term strategic priorities while driving results in the face of macro-
environment headwinds
We continue to transform our portfolio, the recent addition of an IOS business supports
our long-term transformation and is an important step in our journey to digitize,
personalize and democratize dental care
3
Results relate only to continuing operations except for cash flow measures.
*Core sales growth and adjusted EBITDA margin are non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.
EnvistaView entire presentation